Non-Invasive Prenatal Testing Market Growth - CAGR of 13.9% During Forecast Period 2020-2027
Increasing demand for genetic testing in fetuses due to growing incidences of genetic disorders, integration of advanced bioinformatics to provide accurate information about the baby, and rising need for non-invasive testing methods are some key factors expected to drive Non-Invasive Prenatal Testing market growth.
Emergen Research has recently published its latest report titled “Global Non-Invasive Prenatal Testing Market By Method, By End-Use, By Application, By Region Forecast to 2027.”
According to Emergen Research, the global non-invasive prenatal testing market size was USD 3.08 billion in 2019 and is expected to reach USD 8.75 billion in 2027 and register a CAGR of 13.9% during the forecast period, 2017-2027.
Prenatal detection of chromosomal abnormalities has been offered by the healthcare sector for over four decades. Better understanding of the link between higher maternal age and genetic disorder has increased the use of prenatal testing among older mothers. Non-invasive tests are being developed due to the risks that invasive prenatal diagnostic tests such as amniocentesis and chorionic villus sampling carry. Non-invasive prenatal testing involves a simple blood screening that effectively analyzes fetal DNA to pinpoint and detect baby’s risks for a number of genetic disorders. Increasing incidence of chromosomal anomalies, high maternal age, and rising awareness and knowledge regarding the benefits of prenatal testing are some key factors expected to drive market revenue growth over the forecast period.
In addition, advancements in non-invasive testing methods, growing incidence of pregnancy-related complications in second- or third-trimesters, and increasing adoption of prenatal testing for high-risk pregnancies are some other factors expected to fuel revenue growth of the market over the forecast period.
Non-invasive prenatal testing (NIPT) offers early genetic screening for chromosomal conditions using a small amount of blood. It offers genetic analysis as early as 10 weeks into the pregnancy and often has high detection rates, little to no risk to mother and the baby, and low false-positive rates. Non-invasive prenatal testing cell-free DNA from the maternal blood sample and screens for common chromosomal anomalies such as Down’s syndrome, Edwards syndrome, or Patau syndrome. The specificity and sensitivity of NIPT is high and the test generally reduces the need for invasive screening tests which pose a risk to the pregnant women. According to certain research studies, NIPTs have an accuracy rate of 97-99% when it comes to predicting the risk of common genetic disorders. These tests create fewer false alarms than standard first-trimester blood screenings and hence are widely adopted by the doctors for genetic testing in high risk pregnancies. Increasing number of companies offer noninvasive prenatal testing at affordable prices and this is another factor boosting their adoption and is expected to further drive market revenue growth going ahead. However, inaccuracy of these tests in detecting rarer genetic conditions, low accessibility to advanced noninvasive prenatal testing, and high incidence of test-related stress, anxiety, and risk of miscarriage are some key factors that can hamper market growth to a certain extent going ahead.
COVID-19 Impact Analysis
- Social distancing and restrictions severely disrupted businesses and operations
- Lockdowns caused disruptions in transportation and logistics
- Impacted manufacturing activities and mining operations globally
- Took a toll on economy of various countries
- Caused sudden and drastic downturn in economic activity
- Disrupted agriculture, fisheries, dairy, and other sectors
- Caused loss of employment and financial crisis
- Supply impacts were further compounded owing to reduced disposable income
- Emergence of variants continue to cause concerns and impact normal routines
Cell-Free DNA in Maternal Plasma Tests Segment to Drive Market Growth:
The cell-free DNA in maternal plasma tests segment is expected to account for largest revenue share over the forecast period attributable to increasing use of cell-free DNA testing to detect selected chromosomal abnormalities, rising research and development activities to expand clinical applications of fetal genetic material analysis, and use of cell-free fetal DNA to detect and exclude genetic conditions that are not present in mother or genetic conditions inherited from the father.
Diagnostic Laboratories Segment to Register Robust Revenue Growth:
Diagnostic laboratories segment is expected to register robust revenue growth rate over the forecast period attributable to increasing advancements in diagnostic laboratories, availability of high-end diagnostic testing, and implementation of programs to include efficient prenatal testing and genetic testing.
North America to Account for Largest Revenue Share:
North America is expected to account for largest revenue share in the global market over the forecast period. This can be attributable to increasing advancements in healthcare infrastructure, growing awareness regarding early genetic testing in pregnancy, availability and access to advanced prenatal and pregnancy testing, robust research and development activities, high incidences of genetic disorders and growing focus on early diagnosis, and presence of key players in the market.
Major Companies in the Market Include:
- Yourgene Health
- Illumina Inc.
- Agilent Technologies Inc.
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Laboratory Corporation of America Holdings
- GE Healthcare
- PerkinElmer Inc.
- Natera Inc.
For the purpose of this report, Emergen Research has segmented the global non-invasive prenatal testing market based on the method, end-use, application, and region:
Method Outlook (Revenue, USD Billion; 2017-2027)
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-free DNA in Maternal Plasma Tests
End-Use Outlook (Revenue, USD Billion; 2017-2027)
- Diagnostic Laboratories
- Research Centers
Application Outlook (Revenue, USD Billion; 2017-2027)
- Microdeletion Syndrome
Regional Outlook (Revenue, USD Billion; 2017-2027)
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Cell-Free DNA (cfDNA) Testing Market Size Worth USD 22.41 Billion by 2027 | CAGR of 26.2%
Prefilled Syringes Market Size Worth USD 9.11 Billion by 2027 | CAGR of 8.9%
Assisted Reproductive Technology (ART) Market Size Worth USD 50.32 Billion by 2027 | CAGR of 9.3%
Alopecia Market Size Worth USD 5,250.8 Million by 2027 | CAGR of 8.9%
Synthetic Blood Substitutes Market Size Worth USD 15.40 Billion by 2027 | CAGR of 18.5%
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
Visit for More Insights: https://www.emergenresearch.com/insights
Read Our Press release@ https://www.emergenresearch.com/press-release/global-non-invasive-prenatal-testing-market